Hologic's CEO presented a strategic overview at the J.P. Morgan Healthcare Conference, highlighting the company's strong financial performance since 2014. Revenue grew from approximately $2.5 billion to over $4 billion, representing a compound annual growth rate of 4.8%.
Non-GAAP EPS increased from $1.46 to $4.08 over the same period, achieving a compound annual growth rate of 10.8%. The presentation emphasized the expansion of molecular diagnostics, with Panther placements growing to over 3,300 globally.
Recent strategic moves included the FDA approval of the Genius Digital Diagnostics system for cytology and the unveiling of the next-generation Envision mammography platform in December 2024. The company also completed the Endomagnetics acquisition for $310 million and the Gynesonics acquisition for $350 million in early fiscal 2025, alongside significant share repurchases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.